Results 161 to 170 of about 15,304,481 (401)

TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells.

open access: yesCancer Research, 2017
Taiwen Li   +9 more
semanticscholar   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

open access: yesMolecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson   +2 more
wiley   +1 more source

Hyperbaric Oxygen Potentiates Doxil Antitumor Efficacy by Promoting Tumor Penetration and Sensitizing Cancer Cells [PDF]

open access: gold, 2018
Xian Wu   +6 more
openalex   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

Tumor Cell-Derived Exosomal miR-770 Inhibits M2 Macrophage Polarization via Targeting MAP3K1 to Inhibit the Invasion of Non-small Cell Lung Cancer Cells

open access: gold, 2021
Jixian Liu   +8 more
openalex   +1 more source

Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

open access: yesNew England Journal of Medicine, 2004
M. Cristofanilli   +10 more
semanticscholar   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Galectin-3 in the Lung Cancer Microenvironment: 
Immunomodulation and Therapeutic Breakthroughs

open access: yesChinese Journal of Lung Cancer
Lung cancer remains one of the most prevalent and deadly malignancies worldwide, with persistently low five-year survival rates. This poor prognosis is primarily attributed to challenges such as difficulties in early diagnosis, high tumor heterogeneity ...
Hongbao ZHU, Jiong DENG, Tong WANG
doaj   +1 more source

Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T-Cell Exhaustion

open access: green, 2020
Song Yao   +15 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy